99mTc-3PRGD2 SPECT to monitor early response to neoadjuvant chemotherapy in stage II and III breast cancer

Purpose Monitoring of response to neoadjuvant chemotherapy (NCT) is important for optimal management of patients with breast cancer. 99mTc-3PRGD2 SPECT is a newly developed imaging modality for evaluating tumor vascular status. In this study, we investigated the application of 99mTc-3PRGD2 SPECT in evaluating therapy response to NCT in patients with stage II or III breast cancer.